Cohort study of patients with blood cancers in Languedoc-Roussillon
Prospective Cohort Study of Clinical and Laboratory Data of Patients With Hemopathy in Languedoc-Roussillon
This study is tracking adults with blood cancers like lymphoma and leukemia to see how these diseases develop over time and improve future treatments.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Montpellier Academic / other |
| Locations | 1 site (Montpellier) |
| Trial ID | NCT02134574 on ClinicalTrials.gov |
What this trial studies
This observational study collects clinical and laboratory data from patients diagnosed with hematologic malignancies, such as lymphoma, leukemia, and multiple myeloma. It aims to better understand the characteristics and progression of these conditions by following a cohort of patients over time. Participants must be adults with either a suspected or recently diagnosed blood cancer, and they will provide informed consent to be part of the study. The data gathered will help inform future treatment approaches and improve patient care.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 years old with suspected or newly diagnosed hematologic malignancies.
Not a fit: Patients who have previously received treatment for hematological conditions will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of hematologic malignancies and lead to improved treatment strategies for patients.
How similar studies have performed: While this study follows a common observational approach, the specific focus on the Languedoc-Roussillon region may provide novel insights into local patient populations.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria: * Age over 18 * Consultant or hospitalized patient for suspected malignant hemopathy and justifying further exploration or patient with a diagnosis of malignant hemopathy less than 6 months old at the time of signing the consent * Having signed an informed consent * Affiliated with a social security scheme Exclusion criteria: * Minor or major protected * Patients who have received treatment for hematological pathology
Where this trial is running
Montpellier
- Hematology department - UHMontpellier Saint éloi — Montpellier, France (Recruiting)
Study contacts
- Principal investigator: Guillaume Cartron — University Hospital, Montpellier
- Study coordinator: Valerie ROUILLE
- Email: v-rouille@chu-montpellier.fr
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.